重组人碱性磷酸酶治疗脓毒症相关急性肾损伤的3期试验(REVIVAL)
REVIVAL是一项国际双盲随机对照3期试验,纳入使用血管升压药<72小时且AKI<24小时的脓毒症相关急性肾损伤患者,比较伊洛福司α与安慰剂。主要终点28天全因死亡率两组均为27.9%,试验因主要终点无效提前终止;90天死亡率伊洛福司α组33.9% vs 安慰剂组34.8%。MAKE90A和MAKE90B在伊洛福司α组分别为56.7%和37.4%,安慰剂组为64.6%和42.8%;不良事件发生率伊洛福司α组67.9% vs 安慰剂组75%。结论认为伊洛福司α未改善28天生存,但可能减少MAKE90事件,未发现安全性问题。
要点
- 主要终点28天全因死亡率伊洛福司α组与安慰剂组均为27.9%,试验因主要终点无效提前终止。
- 90天死亡率伊洛福司α组33.9% vs 安慰剂组34.8%。
- MAKE90A发生率伊洛福司α组56.7% vs 安慰剂组64.6%;MAKE90B发生率伊洛福司α组37.4% vs 安慰剂组42.8%。
- 28天内无器官支持存活天数中位数伊洛福司α组17天[IQR 0-24] vs 安慰剂组14天[IQR 0-24]。
- 不良事件发生率伊洛福司α组67.9% vs 安慰剂组75%。
适用人群与场景
- 脓毒症相关急性肾损伤(SA-AKI)危重患者,纳入标准为使用血管升压药<72小时且AKI<24小时。
研究设计与关键结果
- 国际双盲随机对照3期试验,650例接受治疗并纳入安全性分析,649例纳入疗效分析(伊洛福司α组n=330,安慰剂组n=319)。
- 主要终点28天全因死亡率伊洛福司α组27.9% vs 安慰剂组27.9%,试验因主要终点无效提前终止。
- 90天死亡率伊洛福司α组33.9% vs 安慰剂组34.8%。
- MAKE90A发生率伊洛福司α组56.7% vs 安慰剂组64.6%;MAKE90B发生率伊洛福司α组37.4% vs 安慰剂组42.8%。
- 28天内无器官支持存活天数中位数[IQR]伊洛福司α组17[0-24]天 vs 安慰剂组14[0-24]天。
- 28天内存活且出ICU天数中位数[IQR]伊洛福司α组15[0-22]天 vs 安慰剂组10[0-22]天。
- 不良事件发生率伊洛福司α组67.9% vs 安慰剂组75%。
证据类型、等级与局限
- 证据类型:国际双盲随机对照3期试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在脓毒症相关急性肾损伤危重患者中,伊洛福司α未改善28天生存,但可能减少MAKE90事件,未发现安全性问题。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Ilofotase alfa is a human recombinant alkaline phosphatase with reno-protective effects that showed improved survival and reduced Major Adverse Kidney Events by 90 days (MAKE90) in sepsis-associated acute kidney injury (SA-AKI) patients. REVIVAL, was a phase-3 trial conducted to confirm its efficacy and safety.
METHODS: In this international double-blinded randomized-controlled trial, SA-AKI patients were enrolled < 72 h on vasopressor and < 24 h of AKI. The primary endpoint was 28-day all-cause mortality. The main secondary endpoint was MAKE90, other secondary endpoints were (i) days alive and free of organ support through day 28, (ii) days alive and out of the intensive care unit (ICU) through day 28, and (iii) time to death through day 90. Prior to unblinding, the statistical analysis plan was amended, including an updated MAKE90 definition.
RESULTS: Six hundred fifty patients were treated and analyzed for safety; and 649 for efficacy data (ilofotase alfa n = 330; placebo n = 319). The observed mortality rates in the ilofotase alfa and placebo groups were 27.9% and 27.9% at 28 days, and 33.9% and 34.8% at 90 days. The trial was stopped for futility on the primary endpoint. The observed proportion of patients with MAKE90A and MAKE90B were 56.7% and 37.4% in the ilofotase alfa group vs. 64.6% and 42.8% in the placebo group. Median [interquartile range (IQR)] days alive and free of organ support were 17 [0-24] and 14 [0-24], number of days alive and discharged from the ICU through day 28 were 15 [0-22] and 10 [0-22] in the ilofotase alfa and placebo groups, respectively. Adverse events were reported in 67.9% and 75% patients in the ilofotase and placebo group.
CONCLUSION: Among critically ill patients with SA-AKI, ilofotase alfa did not improve day 28 survival. There may, however, be reduced MAKE90 events. No safety concerns were identified.
参考来源
- Pickkers P, Angus DC, Bass K, et al. Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL). Intensive Care Med. 2024. PMID: 38172296. doi:10.1007/s00134-023-07271-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。